FEB 26, 2019 09:00 AM PST
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar

Integration of Technology, Process and Quality Control: Protecting Complete Sample Chain of Custody

SPONSORED BY: Brooks Life Sciences
C.E. CREDITS: P.A.C.E. CE | Florida CE
Speakers
  • Professor of Genetics Rutgers University; COO RUCDR Infinite Biologics; CSO Brooks Life Sciences
    Biography
      Dr. Andy Brooks serves as the Chief Scientific Officer for Brooks Life Sciences. Dr. Brooks is also the Chief Operating Officer and Director of Technology Development of RUCDR Infinite Biologics at Rutgers University. As the Chief Operating Officer of RUCDR Infinite Biologics, Dr. Brooks oversees the operations of all laboratories within RUCDR, ensuring consistent and superior quality standards for all services. RUCDR Infinite Biologics, is the world's largest university-based biorepository with a focus on creating and implementing technologies for biomaterial quality control and sample chain of custody. Dr. Brooks is a molecular neuroscientist, whose research focuses on deciphering the molecular mechanisms that underlie memory and learning. Dr. Brooks is a well-recognized genomicist and has been involved in the development and implementation of cutting edge molecular based technologies for both nucleic acid and protein analyses. He has worked to automate and develop the service infrastructure to provide high-throughput sample management and analysis for DNA, RNA, and protein-based technologies to hundreds of labs globally.
    • Faculty Investigator, Director Genomic Services Laboratory, Executive Director Clinical Services Laboratory HudsonAlpha Institute for Biotechnology
      Biography
        Shawn Levy, PhD is a Faculty Investigator at the HudsonAlpha Institute for Biotechnology in Huntsville, AL and the Director of the Genomics Services Laboratory and the Clinical Services Laboratory. Dr. Levy received his PhD in Biochemistry from Emory University in 2000 and shortly after joined the faculty of Vanderbilt University Medical Center. Dr. Levy joined HudsonAlpha in August 2009 and established the Genomics Services Laboratory (GSL). Since its inception, the GSL has supported more than 4,600 projects from around the world as a comprehensive genomics facility. Dr. Levy is adjunct faculty in the Department of Genetics and Department of Epidemiology at the University of Alabama-Birmingham. He is an author or co-author on more than 150 peer-reviewed publications and his research interests include environmental genomics, technology and methods development in high-performance sequencing for gene expression profiling, genotyping, and structural and functional genomics.

        The HudsonAlpha Institute is a private, non-profit research institute with a three-pronged mission of genomics research, educational outreach and economic development. In addition to individual research awards, the research portfolio of HudsonAlpha includes participation in the The Cancer Genome Atlas Project, the ENCODE project, a Center for Excellence in Genome Sciences, several center grants as well as research awards from NASA and the military.
      • Co-Founder and Chief Scientific Officer, LifeVault Bio
        Biography
          Brad is the co-founder and Chief Scientific Officer for LifeVault Bio, a company dedicated to improving human health through the storage, analysis and potential therapeutic application of biological components derived from peripheral blood. As Chief Scientifc Officer he's responsible for the scientific programs and technologies employed within the company. Prior to co-founding LifeVaultBio, Brad was the Chief Technology Officer for ReproCELL, Inc, a multinational stem cell company focused on the development of novel stem cell technologies and applications for research, discovery and therapeutic programs.Preceding work as a founding Scientist and Director of Research and Development for Stemgent, Inc. resulted in the development of groundbreaking RNA-mediated cellular reprogramming technologies and applications for the generation of induced pluripotent stem (iPS) cells from clinically accessible samples such as human skin, blood and urine. Brad has both published and presented this work internationally and is a member of the International Society of Stem Cell Research (ISSCR), serving on the Industry Committee since 2016. Prior to joining the field of stem cell research, Brad led research teams at RheoGene and Upstate Biotech (acquired by Millipore) focused on the development of novel discovery technologies such as orthoganol, inducible mammalian gene expression switches and RNAi screening platforms.
        • Chief Scientific Officer, Integrated Biobank of Luxembourg
          Biography
            Since February 2010 Dr Betsou is Chief Scientific Officer at IBBL (Integrated Biobank of Luxembourg), where she is directing activities of the Biorefinery and Biospecimen Research laboratory. She is a molecular biologist with 30 years of experience in molecular diagnostics, disease-oriented biobanking and biospecimen research, and 15 years of experience in ISO 9001 and ISO 17025 application to biobanks.
            Dr. Betsou holds 3 patents and is the author of more than 100 peer-reviewed publications, including many fundamental and experimental works on biospecimen research.
            After her PhD, Dr Betsou worked in the diagnostics industry on the development of molecular and immunological diagnostic tests in microbiology. She then became Head Laboratory Manager at a European biobank where she led the work bringing the biobank to ISO certification for all biobanking activities, including Quality Control and methods validation.
            She is an active member of ISBER (International Society for Biological and Environmental Repositories), acting as the chair of the ISBER Biospecimen Science Working Group and of the Proficiency Testing Advisory Group.
            She is also Luxembourg national delegate in ISO REMCO and ISO TC276, and teaches biospecimen science and quality control in several biobanking training courses in Europe.

          Abstract:
          DATE:  February 26, 2019
          TIME:   9:00am PST, 12:00pm EST
           
          Implementation of biobanking best practices and analytical platform standardization are two important components for any data generation associated with state of the art biobanks that support precision medicine applications. Sample collection, pre analytical variables, controlled environment storage and sample processing can often have a large impact on the quality of biomaterials. This roundtable will describe how to standardize biobanking efforts in a manner commensurate with both academic and industrial partnerships. Data will be presented on the governance of biosample collections, standardization efforts, and quality control harmonization for biosamples as well as global best practices for the regulatory oversight of national and commercial biobank resources. Finally, a review of several international programs will illustrate how collaborative efforts are helping advance integrated biobanking precision medicine across many research and clinical areas.
           
          Learning Objectives:
          • Discussion on biobank standards and how they impact sample chain of custody
          • Discussion on sample management and processing quality control tools and how they enable harmonization
          • Discussion on collaborative biobank efforts in precision medicine

          Show Resources
          Show Resources
          Event Countdown
          • 0 Days
          • 0 Hours
          • 0 Minutes
          • 0 Seconds